Amlo Biosciences is a technology company.
Amlo Biosciences has raised $2.0M across 1 funding round.
Amlo Biosciences has raised $2.0M in total across 1 funding round.
Amlo Biosciences has raised $2.0M in total across 1 funding round.
Amlo Biosciences's investors include Northstar Ventures.
AMLo Biosciences is a medtech company developing prognostic and diagnostic tests for skin cancers, primarily targeting early-stage cutaneous melanoma. Its flagship product, AMBLor, is a "rule-out" test using immunohistochemistry to identify low-risk melanomas, stratifying patients for appropriate treatment and surveillance, reducing unnecessary procedures, patient anxiety, and healthcare costs.[1][2][3] The company serves dermatologists, oncologists, and health systems in the UK, US, and Australia, addressing over-treatment in early-stage cases where most patients do not progress to metastasis.[3][5] Since spinning out in 2017, AMLo has raised nearly £5m across funding rounds, grown to 15 employees, achieved ISO 13485 accreditation in 2023, and launched AMBLor via partnerships like Avero Diagnostics in the US, with three additional products in late-stage R&D.[1][2]
AMLo Biosciences spun out from Newcastle University in 2017, translating academic research in cancer biomarkers into commercial diagnostics.[1][2][4] Founded by an all-female academic and management team—led by CEO and co-founder Dr. Marie Labus—the company started as a "two-woman band" focused on improving skin cancer outcomes and cutting healthcare costs.[2] Key early traction included securing IP protection with rapid European patent grants within three years, enabling commercialization.[4] Pivotal moments: £2.45m raised in 2020 (including from NorthStar Ventures, Future Planet Capital, and others) to fund clinical studies and launches in UK/US (2022) and Australia (2023); additional £2.5m in 2020 for team growth and regulatory hires; and ISO 13485 accreditation in January 2023.[1][3][5][6] By 2020, it relocated to The Biosphere in Newcastle Helix, scaling to 12-15 employees while subcontracting locally.[2]
AMLo rides the precision oncology wave, where biomarker-driven diagnostics shift reactive cancer care to proactive, risk-stratified models, fueled by rising skin cancer incidence and demands for cost-efficient health systems.[1][3] Timing aligns with post-pandemic regulatory accelerations (e.g., ISO 13485) and US market potential (50% of global demand), amplified by partnerships like Avero Diagnostics.[1][7] Market forces favoring AMLo include over-treatment costs in melanoma surveillance—saving millions via "rule-out" tests—and growing medtech investment in non-invasive tools.[1][2][5] It influences the ecosystem by validating university spin-outs in the UK North East, creating jobs via Newcastle Helix, and paving the way for IHC-based tests in other cancers.[2][3]
AMLo is poised for US expansion with a planned £2.5-3m raise to establish its own lab, bypassing partnerships for direct testing control amid soft-launch success.[1] Trends like AI-enhanced biomarkers and global guideline inclusions will accelerate adoption, while pipeline validation could double addressable markets in high-risk melanoma and squamous cell carcinoma.[1] Its influence may evolve from regional spin-out to global diagnostics player, potentially attracting big pharma partnerships as precision medtech scales—transforming skin cancer management from the ground up, much like its origin in overlooked academic biomarkers.[1][3]
Amlo Biosciences has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Venture Round in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $2.0M Venture Round | Northstar Ventures |